prof. dr. J.W.A. (John) Rossen
Research interests
Prof. Dr. John W.A. Rossen is Professor of
Medical Microbiology (Personalized Molecular Microbiology) at the
University of Groningen (UMCG) and Isala Hospital (Zwolle, NL), and
Medical Head of Innovation & Science at Isala. With 30+ years
of experience in molecular biology, virology, and microbiology, he
has authored 240+ peer-reviewed publications and is internationally
recognized for bridging science, healthcare, and innovation —
translating research into transformative clinical practice.
He holds a BSc in Mathematics & Physics, an MSc in Biology, and
a PhD in Molecular Virology and Cell Biology (Utrecht University,
1996, coronavirus–host interactions). His career includes
leadership roles such as Director of R&D and Head of
Microbiology & Product Strategy at IDbyDNA (USA), and
Scientific Lead of the €7M Horizon Europe project DRAIGON
(draigon.eu). He also serves as Adjunct Professor at the University
of Utah School of Medicine.
As Medical Head of Innovation & Science at Isala, John drives
healthcare transformation by integrating advanced diagnostics, data
science, and artificial intelligence into clinical workflows.
Working at the intersection of microbiology, infection prevention,
digital health, and hospital strategy, he designs scalable
innovation pathways that move discoveries from bench to bedside and
shape a culture where evidence, technology, and patient outcomes
evolve together.
Talent development is central to his mission. John has supervised
26 PhD students and is committed to nurturing the next generation
of researchers — guiding them in rigorous scientific
thinking, methodological excellence, and the broader skills needed
for successful careers in academia, industry, and healthcare. He
also contributes to international training through the Concilium
Medical Molecular Microbiology and the NVMM Working Group for
International Medical Microbiology.
His research group, Antimicrobial Resistance, Genomics, and
Epidemiology (AGE), applies a One Health approach to study
antimicrobial resistance (AMR) and emerging pathogens across human,
animal, and environmental domains. Combining advanced molecular
tools with AI and machine learning, AGE uncovers resistance and
virulence mechanisms, maps transmission pathways, and develops
predictive models of resistance emergence, disease outcomes, and
outbreak potential — directly supporting antimicrobial
stewardship, infection prevention, clinical decision support, and
evidence-based public health policy.